Aiyuan Wang
Research Subjects
Research Interests
Aiyuan Wang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Fan-Guo Meng
Yangtze Delta Region Institute of Tsinghua University
1 shared publication - Hai-Meng Zhou
Protein Science Laboratory of the Ministry of Education, School of Life Sciences, Tsinghua University, Beijing 100084, China
1 shared publication - Wen-Bin Ou
Zhejiang provincial key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China
1 shared publication - Yisheng Jiao
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, P. R. China
1 shared publication
Latest Publications
- Open Access
- 1 January 2011
- Published by Springer Nature in Molecular Cancer
- Vol. 10 (1) , 125
Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation
Ovarian cancer has the highest mortality rate of all gynecologic malignancy. The receptor tyrosine kinases (RTKs), including EGFR, ERBB2, PDGFR, VEGFR and MET, are activated in subsets of ovarian cancer, suggesting that these kinases might represent novel therapeutic targets. However, clinical trials have not or just partially shown benefit to ovarian cancers treated with EGFR, ERBB2, or PDGFR inhibitors. Despite multiple RTK activation in ovarian cancer pathogenesis, it is unclear whether transforming activity is dependent on an individual kinase oncoprotein or the coordinated activity of multiple kinases. We hypothesized that a coordinated network of multi-RTK activation is important for the tumorigenesis of ovarian cancers.
- 1 January 2011
- Published by Springer Nature in Molecular Cancer
- Vol. 10 (1) , 125
Open AccessTargeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation
Ovarian cancer has the highest mortality rate of all gynecologic malignancy. The receptor tyrosine kinases (RTKs), including EGFR, ERBB2, PDGFR, VEGFR and MET, are activated in subsets of ovarian cancer, suggesting that these kinases might represent novel therapeutic targets. However, clinical trials have not or just partially shown benefit to ovarian cancers treated with EGFR, ERBB2, or PDGFR inhibitors. Despite multiple RTK activation in ovarian cancer pathogenesis, it is unclear whether transforming activity is dependent on an individual kinase oncoprotein or the coordinated activity of multiple kinases. We hypothesized that a coordinated network of multi-RTK activation is important for the tumorigenesis of ovarian cancers.